Given the complicated regulation functions in different tissues and organs of TCPTP, the development of drugs inhibiting TCPTP with a higher specificity and a better biocompatibility is recognized as a promising therapeutic strategy for diabetes or obesity. The gene discussed is PTPN2; the disease is obesity due to melanocortin 4 receptor deficiency.